JK Tyre & Industries (JKTYRE)

CMP: ₹ 122 Target: ₹ 120 (-2%)

Target Period: 12 months

HOLD

May 23, 2022

Muted performance, debt reduction takes backseat...

About the stock: JK Tyre (JKT) is a leading tyre manufacturer with annual capacity pegged at 5.97 lakh MT. It serves various automotive segments via India, Mexico plants with dominance in truck/bus radial (TBR) space domestically.

- Q4FY22 segment mix truck/bus ~56%, PCR ~26%, 2-W, 3-W ~4%
- Q4FY22 channel mix aftermarket ~54%, OEM ~26%, exports ~20%

Q4FY22 Results: The company reported a muted performance in Q4FY22.

- Consolidated net sales were up 8% QoQ to ₹ 3,312 crore
- EBITDA margins slid 200 bps QoQ to 6.9% amid rise in input cost
- Consequent PAT was at ₹ 40.2 crore was lower by 29.4% QoQ

What should investors do? JKT's share price has de-grown at ~6% CAGR over the past five years (~₹ 166 levels in May 2017), underperforming the Nifty Auto index

 With muted margins in the offering due to elevated commodity costs along with limited b/s de-leveraging due to fresh capex spend we downgrade JKT from BUY to HOLD, await margin recovery before turning decisively positive

Target Price and Valuation: Rolling over our valuations, we now value JKT at ₹ 120 i.e. 5.75x EV/EBITDA on FY24E basis (previous target price ₹ 170).

Key triggers for future price performance:

- Beneficiary of domestic CV upswing & high market share in TBR, \sim 65% sales contribution from the space (India operations) & \sim 56% at consol. level
- Decline in input prices namely natural rubber & crude derivatives and consequent o/p margin expansion as well as cash flow generation
- Building in the visible positives, we build 11% FY22-24E net sales CAGR with margins seen at 9.5% in FY24E on base of higher focus on export markets along with continued focus on premiumisation of products

Alternate Stock Idea: Besides JKT, in our ancillary coverage we like Apollo Tyres.

- India CV revival beneficiary focused on debt reduction, higher return ratios
- BUY with a target price of ₹ 250



CI direc

₹ crore
3,004.3
5,115.2
175.7
7,943.8
172 / 98
₹ 49.3 Crore
₹ 2

Silarenolulily pattern									
	Jun-21	Sep-21	Dec-21	Mar-22					
Promoter	56.2	55.9	55.9	56.3					
FII	6.3	7.8	8.1	8.2					
DII	1.4	1.3	1.3	1.2					
Other	36.1	35.0	34.7	34.4					

Price (Cha	rt						
20000 15000 10000]		سمدا	~~	WAR	4	₩.	200 150 100
5000	7	المعدس	m	~J~V			-	50
0	May-19 ───────────────────────────────────	Nov-19 -	May-20 -	Nov-20 -	May-21 -	Nov-21 -	May-22	0
		— Ni	fty (I	LHS)			JKT	(RHS)

Recent event & key risks

- Posted muted Q4FY22 results
- Key Risk: (i) Higher than anticipated recovery in margin performance, (ii) slower than anticipated sales volume growth

Research Analyst

Shashank Kanodia, CFA shashank.kanodia@icicisecurities.com

Raghvendra Goyal raghvendra.goyal@icicisecurities.com

Key Financial Summary								
Key Financials	FY19	FY20	FY21	FY22P	5 year CAGR (FY17-22)	FY23E	FY24E	2 year CAGR (FY22-24E)
Net Sales	10,369.9	8,724.9	9,102.2	11,983.0	9.3%	13,647.9	14,755.3	11.0%
EBITDA	1,114.1	987.6	1,306.3	1,073.3	-1.1%	1,090.3	1,408.1	14.5%
EBITDA Margins (%)	10.7	11.3	14.4	9.0		8.0	9.5	
Net Profit	176.4	150.8	319.4	210.0	-11.0%	180.0	369.8	32.7%
EPS (₹)	7.8	6.1	13.0	8.5		7.3	15.0	
P/E	15.7	19.9	9.4	14.3		16.7	8.1	
RoNW (%)	7.7	6.5	11.9	7.4		6.0	11.2	
RoCE (%)	9.2	7.4	11.8	8.1		7.7	10.6	

Key takeaways of recent quarter & conference call highlights

Q4FY22 Results

- Among geographies, growth for the quarter was led by Mexican geographies. India revenues increased 4% QoQ to ₹ 2,813.5 crore while Mexico operations posted increase of 13% to ₹ 586.4 crore
- As per management commentary, the company continues to focus on all three channels i.e. OEM, aftermarket and exports and is taking price hikes across product categories and also focusing on premiumisation to improve margins. Capacity utilisation for the guarter was ~87%
- On the margin front, gross margin decline was massive 320 bps sequentially
 with rise in raw material being a key reason for QoQ dip in EBITDA margins.
 India EBIT margins fell ~183 bps QoQ to 3.8%, with Mexico EBIT margins
 down ~100 bps QoQ to 5.7%

Q4FY22 Earnings Conference Call highlights

- The company witnessed highest ever yearly sales mark crossing ₹ 12,000+ crore gross sales in FY22 with total topline at ₹ 11,983 crore up 32% YoY. with exports from India amounting to ₹ 1,873 crore in FY22 vs. ₹ 1,176 crore in FY21 (up 60% YoY) highest ever till now. It is witnessing strong growth in truck, bus, LCV & PV radial tyres and remains bullish on the same
- The management recently approved expansion of PCR tyres with estimated capex of ₹ 530 crore in Banmore plant with resultant capacity up 35% from existing and will be operational by December 2023
- Cavendish revenue for Q4FY22 was at ₹ 848 crore vs. ₹ 791 crore in Q4FY21 with total revenue at ~₹ 3,000 crore, up 16% YoY with export sales seen at ₹ 307 crore. Mexican operation's Q4FY22 revenue was at ₹ 586 crore vs. ₹ 406 crore in Q4FY21 with total topline for FY22 at ₹ 2,120 crore. Operating profit for Mexican operation was at ₹ 187 crore. Tornell witnessed highest market share in Mexico in Q4FY22
- Rise in inventory was due to higher input cost coupled with elongated shipping time whereas receivable was higher due to extended export sales which take a longer time to realise
- Raw material price hike was ~3-4% in Q4FY22 with further price hike in Q1FY23 expected at ~4-5%. Correspondingly it has taken ~1-2% price hike in Q4FY22 with further 4-5% price hike planned in Q1FY23, subject to market conditions
- Growth capex for FY23-24 is ~₹ 766 crore including ₹ 530 crore for PCR capacity expansion and ~₹ 236 for TBR capacity expansion to be operational by end of FY23. JKT incurs maintenance capex of ~₹ 100-150 crore (annually). Growth capex of ~₹ 766 crore holds a revenue potential of ~₹1,000 crore Funding for capex would be primarily done from borrowing and internal cash generation

JKT will focus on smart and premium tyres to improve margins & focus on premiumisation of tyres in PCR & TBR segment with latest puncture guard tyre witnessing good traction within few months of launch

Overall capacity utilisation was at \sim 90%: India standalone \sim 85-90%, CIL \sim 80%; JK Tornell \sim 90%

Gross debt was at $\sim \stackrel{\textstyle \scriptstyle \blacksquare}{_{\sim}} 5,100$ crore as of FY22 end

The company is present with popular OEM models like Hyundai Alcazar, TVS Apache, Maruti Suzuki Swift Dzire, Swift, WagonR, Kia Carens & Seltos among others. In Q4FY22 it added Kia Carens as new client for its range of tyres in domestic market

The management expects tyre industry in Mexico to grow in the range of 6-9% in FY23

Export market remains lucrative in terms of margin as price hike are easily absorbed by market but company will focus on domestic market amid buoyant demand prospects


Peer comparison

Exhibit 1: Peer Comparison (tyres)																
Company CMP		TP	Rating	Мсар	EBITI	DA marg	in (%)	Debt	to Equit	ty (x)		RoCE (%	5)	EV/	EBITDA	(x)
Company	₹	₹		₹ crore	FY22	FY23E	FY24E	FY22	FY23E	FY24E	FY22	FY23E	FY24E	FY22	FY23E	FY24E
Apollo Tyres (APOTYR)	217	250	Buy	13,780	12.3	12.5	13.5	0.5	0.4	0.3	6.3	8.1	10.6	7.1	5.9	4.6
Balkrishna Inds (BALIND)	2,110	2,475	Buy	40,790	23.9	23.0	25.0	0.4	0.3	0.2	15.9	18.0	21.7	21.5	17.4	13.6
JK Tyre (JKTYRE)	122	120	Hold	3,004	9.0	8.5	9.0	1.8	1.8	1.6	8.1	7.7	10.6	7.4	7.5	5.8

Source: Company, ICICI Direct Research


With muted margins in the offering due to elevated commodity costs along with limited b/s de-leveraging due to fresh capex spend we downgrade JKT to **HOLD** await margin recovery before turning decisively positive.

Financial story in charts




We expect sales to grow at a CAGR of 11% over FY22-24E to ₹ 14,755 crore in FY24E

Source: Company, ICICI Direct Research




Margins are expected at 9.5% by FY24E vs. 9% clocked in FY22.

Source: Company, ICICI Direct Research




PAT is expected to grow at 32.7% CAGR over FY22-24E.





Return ratios are seen rising to ~10-11% by FY24E

Source: Company, ICICI Direct Research



Net debt is seen rising to $\sim ₹ 5,200$ crore by FY23E and then taper off marginally in FY24E

Source: Company, ICICI Direct Research

Exhibit 7	7: Valuatio	n Summ	nary					
	Sales	Growth	EPS (Diluted)	Growth	PE	EV/EBITDA	RoNW	RoCE
	(₹ cr)	(%)	(₹)	(%)	(x)	(x)	(%)	(%)
FY19	10,369.9	25.4	7.8	167.1	15.7	7.7	7.7	9.2
FY20	8,724.9	(15.9)	6.1	(21.3)	19.9	8.5	6.5	7.4
FY21	9,102.2	4.3	13.0	111.8	9.4	5.7	11.9	11.8
FY22P	11,983.0	31.6	8.5	-34.2	14.3	7.4	7.4	8.1
FY23E	13,647.9	13.9	7.3	-14.3	16.7	7.5	6.0	7.7
FY24E	14,755.3	8.1	15.0	105.5	8.1	5.8	11.2	10.6

Financial Summary

Exhibit 8: Profit and loss	statement			₹ crore
(Year-end March)	FY21	FY22P	FY23E	FY24E
Total operating Income	9,102.2	11,983.0	13,647.9	14,755.3
Growth (%)	4.3	31.6	13.9	8.1
Raw Material Expenses	5,468.7	8,039.3	9,408.8	9,991.3
Employee Expenses	922.7	1,065.4	1,148.7	1,231.7
Other Expenses	1,404.4	1,805.1	2,000.1	2,124.3
Total Operating Expenditure	7,795.9	10,909.7	12,557.5	13,347.2
EBITDA	1306.3	1073.3	1090.3	1408.1
Growth (%)	32.3	-17.8	1.6	29.1
Depreciation	386.7	385.4	395.8	427.9
Interest	465.9	419.1	460.3	456.0
Other Income	43.1	36.6	44.4	48.0
Exceptional Items	-37.5	-3.6	0.0	0.0
PBT	496.9	305.4	278.6	572.2
Total Tax	200.9	108.7	97.5	200.3
PAT	319.4	210.0	180.0	369.8
Growth (%)	111.8	-34.2	-14.3	105.5
EPS (₹)	13.0	8.5	7.3	15.0

Source: Company, Id	CICI Direct Research
---------------------	----------------------

Exhibit 9: Cash flow state	Exhibit 9: Cash flow statement									
(Year-end March)	FY21	FY22P	FY23E	FY24E						
Profit after Tax	319.4	210.0	180.0	369.8						
Add: Depreciation & Int	852.5	804.5	856.1	883.9						
(Inc)/dec in Current Assets	150.5	-1,240.0	-739.0	-478.5						
Inc/(dec) in CL and Provisions	37.6	585.7	348.4	268.4						
CF from operating activities	1360.1	360.2	645.5	1043.5						
(Inc)/dec in Investments	-6.8	14.3	-20.0	-20.0						
(Inc)/dec in Fixed Assets	-262.2	-379.1	-550.0	-550.0						
Others	282.6	1.4	148.3	98.7						
CF from investing activities	13.6	-363.5	-421.7	-471.3						
Issue/(Buy back) of Equity	0.0	0.0	0.0	0.0						
Inc/(dec) in loan funds	-892.6	458.7	300.0	-50.0						
Dividend paid & dividend tax	-49.3	-36.9	-30.8	-61.6						
Others (incl Interest costs)	-394.6	-416.6	-460.3	-456.0						
CF from financing activities	-1336.4	5.2	-191.1	-567.6						
Net Cash flow	37.3	1.9	32.7	4.6						
Opening Cash	136.5	173.8	175.7	208.4						
Closing Cash	173.8	175.7	208.4	213.0						

Source: Company, ICICI Direct Research

Exhibit 10: Balance Sheet				₹ cror
(Year-end March)	FY21	FY22P	FY23E	FY24E
Liabilities				
Equity Capital	49.3	49.3	49.3	49.3
Reserve and Surplus	2,623.5	2,799.1	2,948.2	3,256.4
Total Shareholders funds	2672.8	2848.3	2997.5	3305.7
Total Debt	4,656.5	5,115.2	5,415.2	5,365.2
Deferred Tax Liability	368.3	405.1	461.4	498.8
Other non-current liabilities	809.9	821.2	935.3	1,011.2
Minority Interest	106.3	99.2	99.2	99.2
Total Liabilities	8613.8	9289.1	9908.6	10280.2
Assets				
Gross Block	10,061.9	10,626.9	11,026.9	11,776.9
Less: Acc Depreciation	3,806.8	4,192.2	4,588.0	5,015.9
Net Block	6255.1	6434.7	6438.9	6761.0
Capital WIP	286.4	100.6	250.6	50.6
Total Fixed Assets	6,541.5	6,535.2	6,689.4	6,811.5
Investments	147.0	132.8	152.8	172.8
Inventory	1,789.3	2,432.6	2,617.4	2,829.8
Debtors	1,575.4	1,979.9	2,430.4	2,627.7
Loans and Advances	136.0	208.8	237.9	257.2
Other current assets	417.5	536.9	611.5	661.1
Cash	173.8	175.7	208.4	213.0
Total Current Assets	4,092.0	5,333.9	6,105.6	6,588.7
Creditors	1,574.1	2,188.5	2,430.4	2,627.
Provisions	7.8	17.4	19.3	20.9
Other current liabilities	791.0	752.7	857.3	926.8
Total Current Liabilities	2,372.9	2,958.6	3,307.1	3,575.4
Net Current Assets	1719.1	2375.3	2798.5	3013.3
Others	207.5	235.8	227.2	195.6
Application of Funds	8613.8	9289.1	9908.6	10280.2

Courses Company	ICICI Direct Research
Source. Company,	icici Direct nesearcii

Exhibit 11: Key ratios				
(Year-end March)	FY21	FY22P	FY23E	FY24E
Per share data (₹)				
EPS	13.0	8.5	7.3	15.0
Cash EPS	28.7	24.2	23.4	32.4
BV	108.5	115.7	121.7	134.2
DPS	2.0	1.5	1.3	2.5
Cash Per Share	7.1	7.1	8.5	8.6
Operating Ratios (%)				
EBITDA Margin	14.4	9.0	8.0	9.5
PBIT / Net sales	10.1	5.7	5.1	6.6
PAT Margin	3.3	1.7	1.3	2.5
Inventory days	71.8	74.1	70.0	70.0
Debtor days	63.2	60.3	65.0	65.0
Creditor days	63.1	66.7	65.0	65.0
Net Working Capital days	71.8	67.7	70.0	70.0
Return Ratios (%)				
RoE	11.9	7.4	6.0	11.2
RoCE	11.8	8.1	7.7	10.6
RoIC	12.5	8.4	8.2	10.9
Valuation Ratios (x)				
P/E	10.2	14.5	16.7	8.1
EV / EBITDA	5.7	7.4	7.5	5.8
EV / Net Sales	0.8	0.7	0.6	0.6
Market Cap / Sales	0.3	0.3	0.2	0.2
Price to Book Value	1.1	1.1	1.0	0.9
Solvency Ratios				
Debt/Equity	1.7	1.8	1.8	1.6
Current Ratio	2.5	2.3	2.4	2.4
Quick Ratio	1.3	1.2	1.3	1.3

RATING RATIONALE

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according -to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Shashank Kanodia, CFA, MBA (Capital Markets), and Raghvendra Goyal, CA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number — INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or usi would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eliqible for sale in al jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.